.png)
NX Prenatal provides an unprecedented level of insight into maternal and fetal health through a safe and convenient maternal blood testing approach.
Learn how we can help pregnant moms do the very best they can for their health and their child’s health.
.png)
All key obstetric and pediatric physician groups, as well as child health advocacy groups, are now urging mothers and obstetricians not to deliver babies before 39 weeks unless there is a medical reason to do so. In the last 4 weeks of pregnancy, a baby’s brain, lungs, and liver go through dramatic development and growth, and over 50% of the immune-boosting antibodies are transferred from the mom to the baby during this period.
NX Prenatal is committed to advancing the field of maternal and fetal health in support of the critical goal of delivering healthier babies. To achieve this, we collaborate with world-class institutions to develop groundbreaking molecular tests that can enable personalized maternal-fetal health care delivery and pave the way for new therapeutic innovations.
.png)
.svg)
.png)
.png)
Annual economic
impact to US system
Occur before week 37; physician organizations strongly support initiatives to promote > 39weeks deliveries
Are spontaneous events with no symptoms/warning
1.5M first time moms
Average cost/day can be $7k-$10k
1 week of additional time in utero saves
9.5 days in the NICU
Up to
Prevention of PTB reported w/care protocols initiated by week 16
Our first trimester blood testing approach provides tailored maternal health information earlier than any current test – as early as 9-13 weeks with a standard blood sample during a regular office visit.
NX Prenatal is committed to empowering pregnant women with actionable data to prevent early labor and help reduce complications that could arise from preterm birth.
Preeclampsia is a life-threatening pregnancy complication that’s responsible for 25% of maternal deaths in the developing world and 16% in economically advanced societies. Early detection is crucial, as it can cause immediate complications such as seizures, eclampsia, and organ failure. Studies indicate effective risk stratification for Preeclampsia with our approach as early as week 10-12 of pregnancy.
In addition, NX Prenatal’s recent studies have identified molecular subtypes of preeclampsia that highly correlate with early versus late-onset cases. Combined with tailored maternal health strategies for each pregnancy, we can improve outcomes for mothers and babies and lower maternal mortality rates.
Preeclampsia, HELLP syndrome, and related hypertensive disorders of pregnancy are a leading cause of maternal death
Annual economic impact to US system
for every death, there are at least 50 times more cases of adverse outcomes
of cases have HELPP syndrome symptoms (up to 25% mortality)
of cases result in infant death
Up to
reduction in PE reported w/care protocols initiated by week 16
have higher incidence rates
Pregnancies affected worldwide each year
Placenta accreta occurs when the placenta attaches too deeply to the uterine wall, making it difficult to detach after childbirth. This condition affects a small percentage of pregnancies but can cause severe bleeding and potentially life-threatening complications.
NX Prenatal and its partners have developed groundbreaking technology that detects Placenta Acrreta cases with 83% accuracy enabling mothers to seek delivery with proper specialists in order to prevent complications at birth.
Placenta accreta risk increases with uterine scarring from prior C-Section or other procedures
.svg)
Placenta grows into the muscular later of the uterus
.svg)
Stay up to date about the latest research and developments from NX Prenatal and the medical community.
.svg)
